(ATHA) – StreetInsider.com Reports
-
Athira Pharma Inc. (ATHA) Appoints Javier San Martin as Chief Medical Officer
-
Athira Pharma (ATHA) Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton
-
Athira Pharma (ATHA) Reports Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton
-
Athira Pharma (ATHA) Presents Preclinical Data Further Supporting the Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis
-
Athira Pharma, Inc. (ATHA) Reports In-Line Q2 EPS
-
Athira Pharma (ATHA) PT Lowered to $19 at JMP Securities
-
Athira Pharma Inc. (ATHA) Appoints Andrew Gengos as Chief Financial Officer and Chief Business Officer
-
Athira Pharma (ATHA) PT Lowered to $5 at Mizuho Securities
-
Athira Pharma, Inc. (ATHA) Tops Q1 EPS by 46c
-
Athira Pharma Inc. (ATHA) Presents New Clinical and Preclinical Data
-
Athira Pharma (ATHA) PT Lowered to $10 at BTIG
-
Athira Pharma (ATHA) Presents Preclinical Data Supporting Therapeutic Potential of Fosgonimeton
-
Athira Pharma Inc. (ATHA) to Present Data Supporting Therapeutic Potential of Enhancing HGF/MET Neurotrophic System
-
Athira Pharma Inc. (ATHA) Reports Publication Highlighting Need for Novel Alzheimer’s Disease Treatment Approaches
-
Athira Pharma Inc. (ATHA) Appoints Kevin Church to Chief Scientific Officer
-
Athira Pharma Inc. (ATHA) Presents Preclinical Data Supporting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND
-
Athira Pharma. (ATHA) Highlights Therapeutic Potential of Fosgonimeton in Presentation of Additional Biomarker Data in Mild-to-Moderate Alzheimer’s Disease Patients from ACT-AD Phase 2 Study at CTAD
-
JMP Securities Upgrades Athira Pharma (ATHA) to Market Outperform
-
Athira Pharma Inc. (ATHA) Advances Phase 2/3 LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients
-
Athira Pharma (ATHA) Provides Update on Plans for Ongoing LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients
-
Athira Pharma (ATHA) Presents Data from ACT-AD Phase 2 Proof-of-Concept Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients
-
Athira Pharma (ATHA) Presents Preclinical Data at the Alzheimer's Association International Conference 2022
-
UPDATE: Mizuho Securities Starts Athira Pharma (ATHA) at Buy
-
Athira Pharma (ATHA) PT Lowered to $3 at Goldman Sachs
-
UPDATE: Stifel Downgrades Athira Pharma (ATHA) to Hold
-
Jefferies Downgrades Athira Pharma (ATHA) to Hold
-
JMP Securities Downgrades Athira Pharma (ATHA) to Market Perform
-
Pre-Open Stock Movers 06/22: La-Z-Boy, Winnebago Gain Post Earnings, Coinbase Falls on More Crypto Worries (more...)
-
Athira Pharma (ATHA) Reiterated at Buy by Stifel Despite Price Plunge, Cites $7 Cash per Share and Awaits Further Updates
-
Athira Pharma Inc. (ATHA) plunges 60% after ACT-AD Phase 2 study of Fosgonimeton in Alzheimer’s fails to hit primary endpoint
-
Athira Pharma (ATHA) Reports Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton
-
Stocks with Implied Volatility Movement
-
Stocks with Implied Volatility Movement
-
Stocks with Implied Volatility Movement
-
Stocks with Implied Volatility Movement
-
Stocks with Implied Volatility Movement
-
Athira Pharma Inc. (ATHA) Responds to Richard A. Kayne’s Suspension of His Proxy Contest
-
Athira Pharma Inc. (ATHA) Reports Preclinical Data
-
UPDATE: BTIG Starts Coverage on Athira Pharma (ATHA) at Buy (correction)
-
Athira Pharma Inc. (ATHA) Extends Ongoing Open Label Extension Study for LIFT-AD and ACT-AD Clinical Trials of Fosgonimeton (ATH-1017) for Mild to Moderate Alzheimer’s Disease
-
Athira Pharma Inc. (ATHA) Issues Letter to Shareholders
-
UPDATE: Berenberg Starts Athira Pharma (ATHA) at Buy
-
Athira Pharma Inc. (ATHA) Mails Shareholder Letter Highlighting the Strength of its Board and Record of Deliberate Board Refreshment
-
Stifel Reiterates Buy Rating, $36 Price Target on Athira Pharma (ATHA) Ahead of ATH-1017 Readout
-
Athira Pharma Inc. (ATHA) Highlights Strong Execution of Strategy and Positioning for the Future
-
Athira Pharma Inc. (ATHA) Appoints Michael A. Panzara to its Board
-
Athira Pharma Inc. (ATHA) Reports Baseline Data from ACT-AD Phase 2 Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
-
Athira Pharma (ATHA) Presents Preclinical Data of Fosgonimeton (ATH-1017) and ATH-1020 at ASENT
-
Athira Pharma Inc. (ATHA) Reports Publication of Phase 1 Results for Fosgonimeton (ATH-1017)
-
Athira Pharma Inc. (ATHA) Appoints Grant Pickering to its Board
Back to ATHA Stock Lookup
